Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

Merus (MRUS) N.V. 'announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology(R) Annual Meeting on Monday, June 2 at 9 a.m. – 12:00 p.m. CT.' 'By essentially every metric, we believe these interim data are significantly better than pembrolizumab monotherapy, the control arm of our ongoing phase 3 trial, and underscores the opportunity petosemtamab holds to become a new standard of care, if approved, in head and neck cancer,' said Bill Lundberg, CEO. 'Additionally, we believe our execution is outstanding with rapid site initiation. We are looking forward to potentially sharing top line interim readout of one or both of our phase 3 trials in 2026. Head and neck squamous cell carcinoma is associated with a poor prognosis and high mortality rate, and there remains a need for new treatment options for patients. In my clinic, I have witnessed firsthand profound tumor shrinkage with petosemtamab administration, and the efficacy results petosemtamab has shown thus far in combination with the current standard of care, pembrolizumab. I'm excited by the impressive ORR and durability of those responses, and what these results, if replicated more broadly could mean for the future of our practice in head and neck cancer.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

Boston Omaha Corporation Announces Date for 2025 Annual Meeting of Stockholders

OMAHA, Neb., June 20, 2025--(BUSINESS WIRE)--Boston Omaha Corporation (NYSE: BOC) (the "Company") announced today that the date of its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") will be August 25, 2025. The meeting will be held at The Salvation Army Omaha Kroc Center – Joyce Mammel Assembly Hall, 2825 Y Street, Omaha, NE 68107. The formal portion of the 2025 Annual Meeting will commence at 10:00 a.m. Central Time and will be held in person with no remote streaming. As the 2025 Annual Meeting will be held within 30 days from the anniversary date of the Company's 2024 Annual Meeting, the deadlines set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on August 2, 2024 remain in effect for stockholder proposals and director nominations. If you plan to attend this year's meeting, please RSVP here at our event page: Boston Omaha's 2025 Annual Shareholder Meeting. About Boston Omaha Corporation Boston Omaha Corporation is a public holding company with four majority owned businesses engaged in outdoor advertising, broadband telecommunications services, surety insurance and asset management. Our investor relations website, services as a comprehensive resource for investors. We strongly encourage its use for easy access to information about the Company. We promptly make available on this website, free of charge, the reports that we file or furnish with the SEC, corporate governance information, and select press releases, which may contain material information about us, and you may subscribe to be notified of new information posted to this site. View source version on Contacts Boston Omaha CorporationJosh Weisenburger, 402-210-2633contact@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

an hour ago

• Business Wire

Boston Omaha Corporation Announces Date for 2025 Annual Meeting of Stockholders

OMAHA, Neb.--(BUSINESS WIRE)--Boston Omaha Corporation (NYSE: BOC) (the 'Company') announced today that the date of its 2025 Annual Meeting of Stockholders (the '2025 Annual Meeting') will be August 25, 2025. The meeting will be held at The Salvation Army Omaha Kroc Center – Joyce Mammel Assembly Hall, 2825 Y Street, Omaha, NE 68107. The formal portion of the 2025 Annual Meeting will commence at 10:00 a.m. Central Time and will be held in person with no remote streaming. As the 2025 Annual Meeting will be held within 30 days from the anniversary date of the Company's 2024 Annual Meeting, the deadlines set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on August 2, 2024 remain in effect for stockholder proposals and director nominations. If you plan to attend this year's meeting, please RSVP here at our event page: Boston Omaha's 2025 Annual Shareholder Meeting. About Boston Omaha Corporation Boston Omaha Corporation is a public holding company with four majority owned businesses engaged in outdoor advertising, broadband telecommunications services, surety insurance and asset management. Our investor relations website, services as a comprehensive resource for investors. We strongly encourage its use for easy access to information about the Company. We promptly make available on this website, free of charge, the reports that we file or furnish with the SEC, corporate governance information, and select press releases, which may contain material information about us, and you may subscribe to be notified of new information posted to this site.

Yahoo

7 hours ago

• Yahoo

Transgene completes initial screening in Phase II part of TG4050 vaccine trial

Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio